BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 23578236)

  • 21. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
    Wang J; Cai Y; Ren C; Ittmann M
    Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
    Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
    Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
    Liu W; Ewing CM; Chang BL; Li T; Sun J; Turner AR; Dimitrov L; Zhu Y; Sun J; Kim JW; Zheng SL; Isaacs WB; Xu J
    Genes Chromosomes Cancer; 2007 Nov; 46(11):972-80. PubMed ID: 17654723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
    Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
    J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Hossain D; Bostwick DG
    BJU Int; 2013 May; 111(5):834-5. PubMed ID: 23578235
    [No Abstract]   [Full Text] [Related]  

  • 29. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
    Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
    Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
    Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
    Brase JC; Johannes M; Mannsperger H; Fälth M; Metzger J; Kacprzyk LA; Andrasiuk T; Gade S; Meister M; Sirma H; Sauter G; Simon R; Schlomm T; Beissbarth T; Korf U; Kuner R; Sültmann H
    BMC Cancer; 2011 Dec; 11():507. PubMed ID: 22142399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
    Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
    Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Lorente JA; Fumado L; Serrano L; Serrano S; Lloreta J; Hernández S
    Prostate; 2015 Aug; 75(11):1216-26. PubMed ID: 25939480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
    Esgueva R; Perner S; J LaFargue C; Scheble V; Stephan C; Lein M; Fritzsche FR; Dietel M; Kristiansen G; Rubin MA
    Mod Pathol; 2010 Apr; 23(4):539-46. PubMed ID: 20118910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERG upregulation and related ETS transcription factors in prostate cancer.
    Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH
    Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Truncated ERG proteins affect the aggressiveness of prostate cancer.
    Wu F; Ding S; Lu J
    Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.